CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial.

  • Year: 2016
  • Date: 2016
  • Author: Pincikova T
Source

Eur J Clin Nutr. 2016 Dec 14. doi: 10.1038/ejcn.2016.259.

Study design (if review, criteria of inclusion for studies)

RCT

Participants

Sixteen CF patients

Interventions

Patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (<16 years old) or 7143 IU/day (16 years old) was further individually adjusted. Three months of intervention were followed by two of washout

Outcome measures

s25OHD, plasma IL-8 (P<0.05), adult Quality-of-Life respiratory score, FEV1 and FVC

Main results

To increase s25OHD, the mean daily dose of vitamin D2 and D3 had to be increased up to 15650 and 8184 IU, respectively. The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Patients provided vitamin D3 improved FVC at the end of the trial (P<0.05). Change in s25OHD was positively correlated with changes in the adult Quality-of-Life respiratory score at the end of supplementation (P=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout.

Authors' conclusions

Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF

Keywords: Adult; Aged; Child; non pharmacological intervention - diet; vitamins; Vitamin D; Vitamins; pharmacological_intervention;